Searchable abstracts of presentations at key conferences in endocrinology

ea0032p535 | Endocrine tumours and neoplasia | ECE2013

Adrenal lesions in patients with neuroendocrine tumors

Popovic Bojana , Macut Djuro , Petakov Milan , Bozic Ivana , Bogavac Tamara , Isailovic Tatjana , Ognjanovic Sanja , Elezovic Valentina , Micev Marjan , Menkovic Nemanja , Ilic Dusan , Damjanovic Svetozar

Introduction: The coexistence of adrenal tumors (AT) in patients with neuroendocrine tumors (NETs) has not been extensively studied. The aim of our study was to investigate their prevalence and clinical significance in these patients.Materials and methods: We retrospectively studied 447 patients with NETs of all localizations, treated at our department between 2004 and 2012. Diagnosis was established pathohistologically, classification performed accordin...

ea0073ep126 | Endocrine-Related Cancer | ECE2021

Hyperprogression of Merkel cell carcinoma during immunotherapy

Ivana Bozic-Antic , Jovanovic Marko , Petkovic Ana , Micev Marjan , Popovic Bojana , Ognjanovic Sanja , Tatjana Isailovic , Ilic Dusan , Bogavac Tamara , Opalic Milica , Valentina Elezovic-Kovacevic , Macut Djuro

IntroductionMerkel cell carcinoma-MCC) is a rare, aggressive, neuroendocrine skin tumor with a poor prognosis. Chemotherapy (CT) and/or local/locoregional radiotherapy (LRRT) are first-line MCC therapies, but disseminated/locally advanced MCCs often become resistant to this treatment. The use of programmed cell death receptor1/programmed cell death ligand 1 (PD-1/PD-L1) monoclonal antibodies is a new type of therapy for MCC. While PD-1 monoclonal antibod...